Description: AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Home Page: www.astrazeneca.com
1 Francis Crick Avenue
Cambridge,
CB2 0AA
United Kingdom
Phone:
44 20 3749 5000
Officers
| Name | Title |
|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board |
| Mr. Chris Sheldon | Head of Investor Relations |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 18.2815 |
|---|---|
| Trailing PE: | 112.4688 |
| Price-to-Book MRQ: | 6.1639 |
| Price-to-Sales TTM: | 4.7349 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 83100 |